Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

26 oct. 2017 16h05 HE | Source: Versartis, Inc.

Versartis Hires Cowen to Assist in Evaluating Potential Strategic Transactions

MENLO PARK, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company, today announced that it has retained Cowen to assist in...
26 oct. 2017 16h05 HE | Source: Versartis, Inc.

Versartis Reports Third Quarter 2017 Financial Results and Provides Corporate Update

MENLO PARK, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company, today announced financial results for the third quarter ended...
21 sept. 2017 16h30 HE | Source: Versartis

Versartis Announces Phase 3 VELOCITY Trial of Somavaratan in Pediatric Growth Hormone Deficiency Did Not Meet Primary Endpoint

MENLO PARK, Calif., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of...
07 sept. 2017 16h05 HE | Source: Versartis

Versartis’ Twice-Monthly Somavaratan for Pediatric Growth Hormone Deficiency to be Featured in Oral and Poster Presentations at IMPE 2017

MENLO PARK, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of...
05 sept. 2017 16h05 HE | Source: Versartis

Versartis Announces Expansion of Executive Leadership Team with Addition of Dr. Robert Gut as the Head of Global Clinical, Medical and Regulatory Affairs

MENLO PARK, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of...
02 août 2017 08h30 HE | Source: Versartis

Versartis to Present at the Canaccord Genuity Growth Conference

MENLO PARK, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of...
27 juil. 2017 16h05 HE | Source: Versartis

Versartis Reports Second Quarter 2017 Financial Results

MENLO PARK, Calif., July 27, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of...
01 juin 2017 08h30 HE | Source: Versartis

Versartis Appoints Eric Dobmeier to Board of Directors

MENLO PARK, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of...
22 mai 2017 08h15 HE | Source: Versartis

Versartis Presents 3-Year Somavaratan Safety and Efficacy Data and Pediatric Program Baseline Demographics at the 19th European Congress of Endocrinology

MENLO PARK, Calif., May 22, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of...
27 avr. 2017 16h05 HE | Source: Versartis

Versartis Reports First Quarter 2017 Financial Results

MENLO PARK, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of...

Page précédente